Perfluorohexyloctane

Perfluorohexyloctane, sold under the brand names EvoTears (Europe), NovaTears (Australia, New Zealand), and Miebo (USA), is a medication used for the treatment of dry eye disease. It is a semifluorinated alkane.

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names EvoTears and NovaTears, and was additionally approved for medical use in the United States in May 2023 under the brand Miebo. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Perfluorohexyloctane when sold under the brand names EvoTears or NovaTears is available in multiple countries over-the-counter costing NZ$34.00, AUD: $30, €30 for approximately a one-month supply. When sold in the USA under the brand Miebo a prescription is required.

Medical uses
Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.